Medi Assist H1 FY27: EBITDA Up 19% to ₹97.2 Cr, Margins Expand to 20.3%
Medi Assist H1 FY27 operating revenue rose 13.0% YoY to ₹478.0 Cr. Operating EBITDA grew 19.0% to ₹97.2 Cr, with margins expanding to 20.3%. The company is debt-free with ₹268.3 Cr in cash. The Board approved a share buyback of up to ₹49.3 Cr.
The announcement details significant financial performance improvements, strategic growth initiatives (technology adoption, international expansion), and capital allocation decisions (buyback), all of which are material to investors and the company's market position.
The company reported strong year-over-year growth in revenue, EBITDA, and profits, along with expanding margins. The debt-free status and significant cash reserves, coupled with an approved share buyback, indicate financial health and confidence in future performance.
Medi Assist Healthcare Services Limited announced its financial results for the first half of fiscal year 2027 (H1 FY27), reporting a 13.0% year-over-year increase in operating revenue to ₹478.0 crore. Operating EBITDA grew by 19.0% to ₹97.2 crore, with EBITDA margins expanding by 103 basis points to 20.3%. Total premiums under management across platform and TPA operations reached ₹24,752 crore. Profit Before Tax (PBT) saw a significant rise of 47.0% year-over-year, and Profit After Tax (PAT) increased by 59.5% year-over-year. The company, India's largest group health administrator, maintained its debt-free status, holding ₹268.3 crore in cash and cash equivalents.
Key operational highlights include a market share of 34.1% in the group health benefits market with 90.5% client retention. Group premiums under management grew 21.8% year-over-year to ₹13,939 crore. The transition to a hybrid retail model has made accessible retail premiums across TPA and Platform models reach 34.1% of the market. Profitability growth outpaced revenue growth, with EBITDA margins reaching 20.4% in Q2 FY27 and 20.3% in H1 FY27.
Technology monetization accelerated, with SaaS and licensing revenue growing 83.8% year-over-year to ₹18.1 crore in H1 FY27. Three of seven contracted insurers are fully live on the technology stack, with the remaining four scheduled to go live in H2 FY27. The company also reported preventing ₹304 crore in fraud, waste, and abuse through its MAven Guard. International expansion via Mayfair We Care reported revenue of ₹20.7 crore in H1 FY27, with platform go-lives in Thailand, Laos, and Cambodia.
The Board of Directors approved a share buyback of up to approximately ₹49.3 crore, funded entirely from internal operating cash flows. This move is intended to enhance Return on Equity (RoE) while preserving liquidity for product development and international growth.
What to do with a filing like this
Medi Assist Healthcare Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medi Assist Healthcare Services Limited. Read the original for the full detail.